Cancer Research UK logo.
SearchDonate
  • Search

A trial looking at bortezomib, adriamycin and dexamethasone as the first treatment for myeloma (PADIMAC)

Overview

Cancer types:

Blood cancers, Myeloma

Status:

Results

Phase:

Phase 2

Details

This trial looked at a combination of bortezomib, adriamycin and dexamethasone (PAD) for myeloma. It was for people who had not had any other treatment for their myeloma.

The trial was open for people to join between 2011 and 2014. The team published the results in 2021.

Recruitment start: 1 March 2011

Recruitment end: 31 January 2014

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Kwee L Yong

Supported by

Blood Cancer UK

Experimental Cancer Medicine Centre (ECMC)

NIHR Clinical Research Network: Cancer

University College London (UCL)

Janssen Cilag

Chugai Pharma UK

Last reviewed: 09 May 2022

CRUK internal database number: 7445

Help and support